Lexaira Bioscience demonstrates high bioavailability in CBD platform
Lexaira Bioscience says its DehydraTECH platform has demonstrated significant improvements to the bioavailability of cannabinoids, and could be applied to other pharmaceuticals.
Top Headlines
Global Industry News
-
Medpace surprises with Q2 2018 revenue growth: ‘Things have been running very smoothly’
from Outsourcing-Pharma.com
-
Celltrion hit with Form 483 over troublesome Incheon plant
from BioPharma-Reporter.com
-
Robotics, automation to play a ‘fundamental role’ in Icon’s continued success: Q2 earnings call
from Outsourcing-Pharma.com
-
Grifols acquires Biotest US in $286m deal
from BioPharma-Reporter.com
Hot Topics
-
Catalent completes Juniper merger to ‘expand and strengthen’ oral dose manufacturing
Mergers and Acquisitions
-
Acorda clinches agreements with circling rivals to key product
Lifecycle Management
-
Novo Nordisk and Signet collaborate to deliver quats to India
Globalisation
-
LEO Pharma aims to be dermatology market leader, acquires Bayer's dermatology unit
Mergers and Acquisitions
